Less RAAS is more, or not

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 11, 2011, Pages 1363-1365

  Shah, Niren K ^a   Choksi, Rushab ^a   Epstein, Benjamin J ^b  

^a East Coast Institute for Research   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ACE escape; ACE inhibitor; aldosterone; angiotensin; angiotensin receptor blocker; blood pressure; direct renin inhibitor; RAAS

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; RAMIPRIL; TELMISARTAN; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MONOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYNCOPE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 80955122866     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.136     Document Type: Review

References (19)

1. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr. Hypertens. Rep. (5), 408-417 (2003).
2. Yusuf S, Sleight P, Pogue J et al.; for The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
3. Fox KM, The European Trial On Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease [EUROPA] Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).Lancet 362, 782-788 (2003).
4. Verma S, Gupta M, Holmes DT et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur. Heart J. 32(17), 2135-2142 (2011).
5. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol. 4(6), 966-972 (1982).
6. Van Den Meiracker AH, Manintveld AJ, Admiraal PH et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J. Hypertens. 10, 803-812 (1992).
7. Brewster U, Perazella MA. The renin- angiotensin-aldosterone system and the kidney: effects on kidney disease. Am. J. Med. 116, 236-272 (2004).
8. Unger T, Sandmann S. Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: conceptual and clinical effects. J. Renin Angiotensin Aldosterone Syst. 1(2 Suppl), S6-S9 (2000).
9. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
10. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370, 221-229 (2007).
11. Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals. Clin. J. Am. Soc. Nephrol. 2(5), 947-955 (2007).
12. Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119, 530-537 (2009).
13. Parving HH, Persson F, Lewis JB et al. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
14. Geiger H, Barranco E, Gorostidi M et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J. Clin. Hypertens. 6, 324-332 (2009).
15. McMurray JJV, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008).
16. Savergnini SQ, Beiman M, Lautner RQ et al. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 56(1), 112-120 (2010).
17. Takai S, Jin D, Miyazaki M. Targets of chymase inhibitors. Expert Opin. Ther. Targets 15(4), 519-527 (2011).
18. Steckelings UM, Larhed M, Hallberg A et al. Non-peptide AT2-receptor agonists. Curr. Opin. Pharmacol. 11(2), 187-192 (2011).
19. Ichihara A, Sakoda M, Kurauchi-Mito A et al. Possible roles of human (pro)renin receptor suggested by recent clinical and experimental findings. Hypertens. Res. 33(3), 177-180 (2010).